AITOPAI热报
USGuidelineConsultationHealthModel providers

Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback

FDA生成式AI医疗器械监管讨论稿（Docket No. FDA-2026-N-7874）
FDA·Published 2026-10-20·Checked by 管理员 on 2026-10-22

The U.S. FDA's Center for Devices and Radiological Health (CDRH) issued a discussion paper on regulating generative AI-enabled medical devices and requested public feedback under Docket No. FDA-2026-N-7874. The paper explores risk assessment approaches for generative AI devices, the applicability of Predetermined Change Control Plans (PCCPs) to generative AI updates, and manufacturer accountability for device outputs. Industry groups including ATA Action have submitted formal comments proposing a two-axis risk framework.

Source ↗Remind meUS · All

What it means for you

  • Generative AI medical device developers can submit feedback during the open docket period and directly shape the future regulatory framework.
  • The discussion paper signals FDA's interest in using PCCPs to allow post-approval iterative updates; product roadmaps should incorporate change control plans.
  • Manufacturer accountability for outputs is on the table; AI medical devices entering the U.S. market need output validation and responsibility mechanisms.

    • What to do

    ComplianceAssess whether to submit comments to the docket, directly or via industry associations, before the deadline
    ProductMap generative AI medical device pipelines and evaluate PCCP applicability and change control design
    LegalTrack FDA's subsequent draft guidance and build a U.S. market access compliance roadmap

    Key dates

    2026-10-20Published

    Source documents

    Source ↗

    Coverage

    Stories in the feed
    Editorial summary, not legal advice; dates and status follow the original document. · Report a correction